Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 33.00
-0.40 (-1.20%)
Aug 19, 2026, 12:15 PM CST
Pharmosa Biopharm Revenue
Pharmosa Biopharm had revenue of 1.79M TWD in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to 69.06M, down -58.77% year-over-year. In the year 2025, Pharmosa Biopharm had annual revenue of 67.27M, down -59.86%.
Revenue (ttm)
69.06M
Revenue Growth
-58.77%
P/S Ratio
80.83
Revenue / Employee
n/a
Employees
40
Market Cap
4.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.27M | -100.30M | -59.86% |
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.34B |
| Mycenax Biotech | 815.87M |
| BioGend Therapeutics | 236.58M |
| Formosa Pharmaceuticals | 52.59M |
| OBI Pharma | 49.68M |
| UnicoCell Biomed | 22.46M |
| Senhwa Biosciences | 1.05M |
| AnnJi Pharmaceutical | 959.00K |